anastrozole has been researched along with Overweight in 3 studies
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months." | 7.80 | Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014) |
| "Estradiol concentrations in postmenopausal women with early, ER-positive breast cancer on anastrozole were significantly different in normal weight versus overweight or obese patients at baseline, but not at 12 and 24 months." | 3.80 | Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. ( Bauer, T; Hadji, P; Hars, O; Knöll, D; Kyvernitakis, I; Struck, M, 2014) |
| "Obesity has been associated with an adverse prognosis and reduced efficacy of endocrine therapy in patients with hormone receptor-positive (HR+) breast cancer (BC)." | 3.30 | The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer. ( de Graaf, H; de Roos, WK; Erdkamp, FLG; Geurts, SME; Honkoop, AH; Imholz, ALT; Kroep, JR; Lammers, SWM; Linn, SC; Smidt, ML; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van der Sangen, MJC; van Hellemond, IEG; Vriens, IJH, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lammers, SWM | 1 |
| Geurts, SME | 1 |
| van Hellemond, IEG | 1 |
| Swinkels, ACP | 1 |
| Smorenburg, CH | 1 |
| van der Sangen, MJC | 1 |
| Kroep, JR | 1 |
| de Graaf, H | 1 |
| Honkoop, AH | 1 |
| Erdkamp, FLG | 1 |
| de Roos, WK | 1 |
| Linn, SC | 1 |
| Imholz, ALT | 1 |
| Smidt, ML | 1 |
| Vriens, IJH | 1 |
| Tjan-Heijnen, VCG | 1 |
| Gnant, M | 1 |
| Pfeiler, G | 1 |
| Stöger, H | 1 |
| Mlineritsch, B | 1 |
| Fitzal, F | 1 |
| Balic, M | 1 |
| Kwasny, W | 1 |
| Seifert, M | 1 |
| Stierer, M | 1 |
| Dubsky, P | 1 |
| Greil, R | 1 |
| Steger, G | 1 |
| Samonigg, H | 1 |
| Fesl, C | 1 |
| Jakesz, R | 1 |
| Kyvernitakis, I | 1 |
| Knöll, D | 1 |
| Struck, M | 1 |
| Hars, O | 1 |
| Bauer, T | 1 |
| Hadji, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open, Comparative Multicentre Trial of 3 Years Anastrozole Treatment vs. 3 Years no Treatment in Postmenopausal Patients With Breast Cancer Who Have Completed 5 Years Adjuvant Hormone Therapy.[NCT00300508] | Phase 3 | 856 participants | Interventional | 1996-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for anastrozole and Overweight
| Article | Year |
|---|---|
The prognostic and predictive effect of body mass index in hormone receptor-positive breast cancer.
Topics: Anastrozole; Body Mass Index; Breast Neoplasms; Female; Humans; Obesity; Overweight; Prognosis | 2023 |
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Topics: Adolescent; Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Body Mass Ind | 2013 |
1 other study available for anastrozole and Overweight
| Article | Year |
|---|---|
Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Topics: Anastrozole; Aromatase Inhibitors; Body Mass Index; Bone and Bones; Breast Neoplasms; Collagen Type | 2014 |